Beneath these discrete signals runs a single structural thread: the widening chasm between political language and operational reality. The Trump administration has spoken openly about psychedelic therapy for veterans — a rhetorically safe position, given the bipartisan reverence for military service and the documented desperation of a veteran suicide crisis that claims roughly 17 lives per day. At 79% confidence, the swarm predicts a federally funded veteran psychedelic pilot will be announced before year-end. At 78% confidence, it predicts that announcement will not translate into a single functioning access program by December 31st. The architecture of the gap is legible: DEA scheduling makes operational implementation legally complex, VA bureaucracy moves on multi-year timescales, and red-state infrastructure — where the political will theoretically exists — has not been built. This is not dysfunction in the ordinary sense. It is a pattern: announcement as a substitute for action, rhetoric as the product itself.
That pattern has human costs that compound quietly. There are veterans in rural Texas, in Appalachian Kentucky, in suburban Arizona — men and women who have heard their president speak of ibogaine and psilocybin, who have told their families that help might finally be coming, who are waiting. Some are managing opioid dependencies that no current VA protocol has meaningfully touched. Some are living inside PTSD symptom profiles that SSRIs have not moved in a decade. The investigative journalists are coming — the swarm gives 81% confidence to at least three major outlet investigations into the rhetoric-access gap before year-end — and when those stories publish, they will carry faces and names. The highest positive outcome available from this particular formation is not a policy reversal or a scheduling change in 2026. It is something smaller and more durable: that the investigations produce enough documented harm to make the gap politically untenable, accelerating real state-level pilots in 2027 rather than 2028. That is the thread worth watching. The signal to track is not the announcement — it is whether any red-state governor ties operational funding to the federal rhetoric before Q4.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
The current is already moving. You are already in it.
93%
No psychedelic drug gets FDA approval in 2026
The FDA (the US drug regulator) won't approve any psychedelic compound for medical use during 2026. This matters because it means patients looking for legal, regulated psychedelic therapy still won't have that option, and companies betting on 2026 approvals will face delays.
→ No psychedelic will be FDA-approved by end of 2026—anyone expecting that should shift their timeline forward by at least one year.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
No psychedelic compound will receive FDA approval in calendar year 2026.. The MDMA NDA remains stalled following the June 2024 AdCom rejection and Lykos's subsequent struggles. No psilocybin NDA is currently filed. FDA's Psychedelic Drugs division has signaled it requires complete Phase 3 data packages with long-term follow-up before approval. Pipeline timelines, CMC requ
81%
Psilocybin won't get FDA approval before September 2028
Psilocybin (the active compound in magic mushrooms) won't receive FDA approval until at least late 2028. This matters because it extends the wait for people with treatment-resistant depression or other conditions who are counting on legal medical access.
→ Psilocybin approval is a 2028–2029 story, not a 2026–2027 one.
Resolves: 2028-09-30 · USA
REGULATION
the precise call ▾
Psilocybin will not receive FDA approval for any indication before 2028-09-30.. No psilocybin NDA is currently on file as of mid-2026. Compass Pathways and Usona are in Phase 3; typical NDA review adds 12–18 months post-submission. Even an optimistic Phase 3 completion by end-2026 implies NDA filing in mid-2027 at earliest, with PDUFA date in late 2028. FDA's post-MDMA posture
78%
DEA will formally oppose psilocybin rescheduling by mid-2027
The DEA (the US drug enforcement agency) will file an official written statement against moving psilocybin out of Schedule I (the strictest legal category) before June 2027. This matters because it's a powerful legal barrier that will slow or block any congressional or administrative push to reschedule the drug.
→ The DEA will put its opposition on paper, creating a legal and political obstacle to rescheduling.
Resolves: 2027-06-30 · USA
REGULATION
the precise call ▾
DEA will file formal written opposition to psilocybin administrative rescheduling by 2027-06-30, explicitly citing longitudinal safety data gaps or diversion risk.. DEA has consistently opposed Schedule I reclassification absent full FDA approval. No national monitoring infrastructure exists for a Schedule III psychedelic. DEA's formal comment process (required under the CSA rulemaking procedure) will produce a documented, falsifiable written objection. This is
74%
Announced veteran psychedelic program enrolls zero patients by end-2026
A federal program offering psychedelic therapy to veterans will be announced (likely with media fanfare) but won't actually treat any patients before the end of 2026. This matters because it shows the gap between political promises and the hard regulatory and logistical work needed to actually deliver treatment.
→ A veteran psychedelic program will be announced but will remain empty of patients throughout 2026.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
A federally funded veteran psychedelic therapy program will be publicly announced but will have zero patients enrolled or treated by 2026-12-31.. Political incentives strongly favor announcement: bipartisan veteran support, Trump rhetoric, Congressional pressure. Operational delivery is blocked by DEA Schedule I status, VA formulary restrictions, absence of trained facilitators, and lack of approved protocols. History of VA pilot programs (e.
62%
Major media outlets expose gap between veteran psychedelic promises and real access by end-2026
At least three major news organizations (New York Times, Washington Post, ProPublica, The Atlantic, or similar) will publish investigations specifically about the mismatch between what politicians promise veterans about psychedelic therapy and what actually gets delivered. This matters because it highlights a real access problem and applies public pressure on agencies and politicians to follow through.
→ Three major news outlets will document that veterans can't actually access the psychedelic therapies politicians promised them.
Resolves: 2026-12-31 · USA
CULTURE
the precise call ▾
At least 3 major national outlet investigations (NYT, WaPo, ProPublica, The Atlantic, or equivalent) will publish pieces specifically documenting the gap between federal veteran psychedelic rhetoric and actual patient access, before 2026-12-31.. The editorial conditions are unusually favorable: a sympathetic victim population (veterans), a documented policy-access gap, bipartisan political stakes, and named sources with lived experience. This story has clear narrative structure and political newsworthiness regardless of administration. 'Maj